Pyridinones as “Property Knobs” in Drug Design: From Tautomers and H-Bonding Fingerprints to Product Selection (Tables A–C)

A large part of medicinal chemistry optimization is really “local part replacement”: instead of rebuilding the scaffold from scratch, you swap an aromatic ring/heteroaromatic ring for a functional module with a more suitable hydrogen-bonding fingerprint, more controllable polarity, and more predictable metabolism. Pyridinones are a classic example of such a module. They resemble pyridines but add a carbonyl group, so they retain the recognition features of an N-containing aromatic heterocycle while introducing polarity and hydrogen-bond behavior closer to a lactam/amide. Reviews also commonly describe pyridinone motifs as a highly active class of structural units in medicinal chemistry.

1. Understanding “Pyridinones”: 2-Pyridinone vs 4-Pyridinone + Tautomerism

A pyridinone is a six-membered N-heterocycle plus an (amide-type) carbonyl C=O, so it often shows a superposition of physicochemical features from both “aromatic heterocycles” and “lactams/amides”.

By the position of the carbonyl relative to the ring nitrogen, the most common forms in medicinal chemistry are:

(a) 2-Pyridinone (pyridin-2(1H)-one / 2-pyridone)

(b) 4-Pyridinone (pyridin-4(1H)-one / 4-pyridone; closely related by tautomerism to 4-hydroxypyridine)

1) Keto/enol (oxo/hydroxy) tautomerism

The IUPAC Gold Book’s key wording for tautomerism is an isomerism in which tautomers “readily interconvertible” exist; tautomerization is often a fast intra- or intermolecular rearrangement process.

2) Pyridinone ↔ Hydroxypyridine

This is essentially the classic lactam ↔ lactim tautomerism.

3) Notes on tautomer populations

In general, media with stronger hydrogen bonding / higher polarity and the solid state tend to favor the oxo (pyridinone/lactam) form, whereas in the gas phase or weakly solvating environments the hydroxy (hydroxypyridine/lactim) form often becomes more prevalent. The ratio can be strongly shifted by substituents, dimerization/aggregation, salt forms, and metal coordination, so modeling and property discussions should include the major tautomers together.

2. “Knob Cards”: Three Key Knobs by Which Pyridinones Tune Properties

Knob	Typical benefits / what it buys you	Trade-offs / boundaries	Fast ways to verify
A｜H-bonding fingerprint & tautomerism (HBD/HBA, lactam↔lactim)	The same core can deliver a more “usable” H-bond pattern. A common 1H-pyridinone provides a C=O acceptor (HBA) plus an N–H donor (HBD), often enabling lactam/peptide-bond-like geometry. In a binding site, it can more readily “match” an H-bond network and help lock a conformation.	Tautomerism can switch the H-bond fingerprint (HBD/HBA may swap). The population depends on solvent, substituents, salt form/coordination, and aggregation; therefore, the “same structure” may behave differently across environments, and modeling/property prediction should explicitly enumerate tautomers.	(1) Tautomer enumeration + computation (including solvation effects); (2) NMR/IR (track C=O, N–H/O–H features and solvent dependence); (3) if available: co-crystal/crystal structures or high-quality docking to validate H-bond geometry.
B｜Basicity / ionization state (weakening the “pyridine-like basic N”)	Compared with pyridine, pyridinones markedly weaken “pyridine-type basicity” and more often appear as neutral / weakly ionizable species. Unsubstituted (1H)-pyridones may also show amphoteric weak acid/weak base behavior; ionization and solubility can shift with pH and microenvironment, so you should validate via linked readouts (pKa/LogD/solubility/permeability).	Improved solubility/permeability is not guaranteed to improve in the same direction: outcomes depend on the whole molecule (other groups, conformation, polymorph/salt form, etc.). Salt forms/coordination can also change apparent behavior.	(1) pKa (experimental or high-quality prediction calibrated by experiments); (2) LogD (pH 7.4) / LogP; (3) solubility (thermodynamic/kinetic); (4) PAMPA or Caco-2 (permeability) + when needed protein binding / free fraction in plasma.
C｜Metabolic profile (more stable vs metabolic activation/trapping risk)	Pyridinones can help redirect or avoid some common metabolic trajectories seen with pyridines; in some projects they improve overall metabolic behavior or mitigate specific metabolic liabilities.	A double-edged sword: some pyridinone-containing structures can undergo metabolic activation to intermediates that may be trapped by nucleophiles (potentially forming adducts with GSH/NAC, etc.). This is not an inevitable risk, but it is worth screening early.	(1) Microsome/hepatocyte stability (Clint, t1/2); (2) GSH (±NAC) trapping + LC–HRMS to check for conjugates; (3) metabolite profiling (soft spots / major pathways), adding CYP phenotyping/inhibition screens if needed.

Additional notes

1. Addendum to B: Unsubstituted (1H)-pyridones can act as weak HBDs, and may also deprotonate at higher pH (forming an anion), showing condition-dependent ionization/solubility changes. This helps explain why “the same pyridinone fragment” does not always improve solubility and permeability in the same direction across different systems.

2. Pyridinones offer a more controllable “tool-like” property set, but the final profile is jointly determined by the whole molecule and the environment. A minimal verification loop (as above) is the fastest way to judge whether this knob is “worth turning”.

3. Three “Classic Roles” of Pyridinones in Drug Design

Role	Core leverage point	Typical benefits	Representative examples
A｜Peptide bond / lactam “mimic module” (peptidomimetic-friendly)	Insert a directional H-bond pair resembling lactams/peptide bonds into a heteroaromatic ring. Under common tautomers, pyridinones often provide a C=O acceptor (HBA), and when not N-substituted can also provide an N–H donor (HBD).	Without obviously “getting bigger/heavier,” it can better match key pocket H-bond networks, stabilize binding poses, and make SAR more interpretable.	(1) HLE inhibitors: 2-pyridinone/2-aminopyridinone-type fragments embed “peptide-bond-like H-bond geometry” into small molecules, aligning more robustly with key H-bonds in enzyme pockets while retaining strong interactions in non-peptidic scaffolds. (2) HRV 3C protease inhibitors: a 2-pyridinone serves as a directional H-bond anchor for positioning/alignment; together with other reactive motifs it can lock the ligand in the active site (and even enable irreversible capture). (3) One-sentence takeaway: package “peptide-style H-bonding” into a small module and use it as an anchor inside a heteroaromatic ring.
B｜Kinase hinge-binding motif (hinge binder; only valid in specific series)	In some kinase systems, pyridinones or fused pyridinone-like rings place 1–2 H-bond sites near the hinge backbone (whether you get a “two-point H-bond” depends on tautomer, N-substitution, and fused-ring orientation).	As a hinge anchor, it can yield clearer, more reproducible binding localization supported by experiments/structures, enabling subsequent selectivity and physicochemical-window optimization (not universal).	(1) JAK1/JAK2 inhibitors (8-oxo-pyridopyrimidine series): a pyridinone-like carbonyl/donor-acceptor pattern forms a stable hinge pairing, making binding registration clearer and facilitating systematic optimization of selectivity and physicochemical properties. (2) One-sentence takeaway: use pyridinone as a “hinge hook”—fix the binding register first, then optimize.
C｜Bioisostere	The essence of bioisosteric replacement is “keep shape/volume broadly similar, but swap key properties.” IUPAC’s definition of bioisostere emphasizes replacing one atom/group with another of “broad similarity.” Pyridine → pyridinone is a common move: with little volume change, you reduce pyridine-like basicity and introduce a C=O acceptor, tuning polarity/H-bonding/ionization.	Typical benefits: shift pKa / LogD / polarity toward a more developable window, or introduce a more controllable H-bond anchor on a heteroaromatic ring (whether it is “better” still depends on the whole molecule).	(1) Pirfenidone: shows that a pyridinone core itself can be drug-like and viable as a central module. (2) Ciclopirox (hydroxypyridone): illustrates that hydroxypyridones can function as stronger polar/coordination-capable pharmacophores. (3) Doravirine: illustrates that in complex drugs, pyridinone-like fragments are often embedded as local “tuning parts” to adjust polarity/H-bonding/ionization rather than labeling the entire drug simply as a “pyridinone drug.” (4) One-sentence takeaway: the goal is “similar shape, but tune basicity, polarity, and H-bond feel to the right setting.”

4. Practical Cautions

1) Tautomerism can change the “H-bonding pattern you think you have”

Pyridinone ↔ hydroxypyridine is a textbook tautomeric system. In polar, H-bond-friendly environments (e.g., water, alcohols), the balance often shifts toward the pyridinone (NH/oxo, lactam) side; in the gas phase or nonpolar solvents, the hydroxy (OH, lactim) fraction increases. The population is strongly modulated by substituents, solvent, concentration/aggregation, and salt form/coordination—so the same “pyridinone fragment” can present different HBD/HBA fingerprints in different environments.

Key point: the H-bonding fingerprint is tethered to the tautomer—determine the major tautomer (condition-dependent) first, then discuss donors/acceptors.

2) N-substitution “turns off” the N–H donor

Unsubstituted pyridinones can often provide an N–H donor. Once N-alkylated or N-acylated, the N–H is gone, so that X–H···Y H-bond (typically N–H···Y) can no longer occur—fundamentally changing whether the ligand can “add one more H-bond” in the pocket.

Key point: N-substitution removes the N–H donor and changes local electronics. It may improve physicochemical properties, but it may also eliminate a critical H-bond anchor and force a binding-mode rearrangement.

3) Assess metabolism early—especially the “activation → nucleophile trapping (GSH/NAC)” pathway

Pyridinones often provide more controllable physicochemical properties, but under certain structural contexts and metabolic environments they may undergo metabolic activation, generating electrophilic intermediates that can be trapped by nucleophiles such as GSH/NAC, forming conjugates. Using pirfenidone as an example, studies report that in vitro metabolic systems it can undergo activation involving enzymes such as CYP (P450) and sulfotransferases (SULT), and pirfenidone-derived GSH/NAC conjugates have been observed in incubations with liver microsomes or primary hepatocytes.

Key point: this is not labeling pyridinones as “dangerous,” but a reminder that a minority of structures may enter metabolic activation pathways—so early GSH/NAC trapping is a prudent screen.

5. Product Selection Guide and Product Tables for Pyridinone-Related Reagents (Tables A–C)

Selection Guide Table

Need / scenario (typical question)	Which table to check first	Why this table is the best fit	Representative content you can find in this table
Core scaffold selection & tautomerism / H-bonding fingerprint benchmarking: need to establish differences among 2-/3-/4-position systems and evaluate how HBD/HBA layouts and tautomerism affect binding modes and physicochemical properties	Table A｜Core scaffolds / derived scaffolds / connection handles & scaffold hopping	Table A concentrates core scaffolds and key variants, ideal for baseline “structure–property–interaction” benchmarking and for selecting starting scaffolds	2/3/4-hydroxypyridines (tautomeric benchmarks), 2,4-dihydroxypyridine, N-substituted pyridinones/hydroxypyridinones, fused pyridinone-like scaffolds, 3D-saturated pyridinone fragments, etc.
“Pyridine → pyridinone” bioisosteric replacement validation: compare basicity/polarity/solubility/metabolic windows and build interpretable property-transfer rules	Table A｜Core scaffolds / derived scaffolds / connection handles & scaffold hopping	Table A includes tautomeric and N-substitution controls, making it easy to deconvolute single-factor contributions such as “introducing a carbonyl” and “donor shut-off”	Tautomeric core benchmarks, 1-methyl-2-pyridone (donor shut-off control), highly polar polyhydroxy cores, etc.
Parallel synthesis / SAR expansion & site scanning: need rapid installation of aryl/heteroaryl/amine/alkynyl substituents to build 5/6-substituted series for activity and property scanning	Table B｜Halogenated, cross-coupling-ready building blocks (library entry points)	Table B provides high-frequency coupling “entry blocks” (Cl/Br/I), best suited for parallel Suzuki, Buchwald–Hartwig, Sonogashira, and related workflows	5/6-chloro, 5/6-bromo, and 5-iodo 2-hydroxypyridine blocks (different reactivity tiers and library-building efficiency)
Series derivatization with connection handles (amidation/salt formation/linker attachment): need a “connectable position” to build pharmacophore–linker–cap series while balancing solubility and exposure	Table A｜Core scaffolds / derived scaffolds / connection handles & scaffold hopping	Table A concentrates carboxylic-acid “handle” blocks for downstream amidation, salt formation, or further functionalization	2-hydroxynicotinic acid, 4-hydroxynicotinic acid, 3-hydroxy-2-pyridinecarboxylic acid, chelidonic acid, etc.
3D-ification / “planarity” optimization: increase Fsp³ and improve selectivity or solubility while retaining pyridinone-like interaction modes	Table A｜Core scaffolds / derived scaffolds / connection handles & scaffold hopping	Table A includes saturated pyridinone fragments and fused scaffolds, suitable for scaffold hopping and 3D exploration	5,6-dihydropyridin-2(1H)-one, 1,6-naphthyridin-2(1H)-one, etc.
Clinical-drug benchmarks / methodological validation: need marketed drugs to support “pyridinone feasibility,” or reference standards for analytics/biological assays	Table C｜Representative drugs/standards + safety assessment reagents	Table C consolidates marketed drugs and classic references for structure–property–activity arguments and method benchmarks	Pirfenidone, Doravirine, Amrinone, etc.
Metabolic activation / reactive-metabolite risk assessment (GSH/NAC trapping): need to screen for electrophilic intermediates or covalent-risk pathways	Table C｜Representative drugs/standards + safety assessment reagents	Table C provides commonly used nucleophile trapping reagents for early in vitro trapping and metabolic-risk screening	Reduced glutathione (GSH), N-acetylcysteine (NAC)

Table A｜Pyridinone Core Scaffolds / Derived Scaffolds / Connection Handles (Carboxylic Acids) & Scaffold Hopping

Category	CAS No.	Aladdin Cat. No.	Name	Spec / Purity	Key properties & uses (pyridinone-related)
Basic core / tautomeric system (2-position)	142-08-5	H108693	2-Hydroxypyridine	≥97%	2-Hydroxypyridine ↔ 2-pyridinone tautomeric benchmark core: used for fragment starts, H-bond geometry validation, and as a baseline reference for “pyridine → pyridinone” replacement strategies. Different databases may list it as 2-pyridone or 2-hydroxypyridine, but it is the same tautomeric system.
Basic core / tautomeric system (3-position)	109-00-2	H434905	3-Hydroxypyridine	≥99%	3-position benchmark core: used to compare how different carbonyl/hydroxy positions change H-bond geometry, enabling “constitutional isomer-level” property/binding-mode exploration.
Basic core / tautomeric system (4-position)	626-64-2	H482399	4-Hydroxypyridine	Reagent grade	4-Hydroxypyridine ↔ 4-pyridinone tautomeric benchmark core; provides a predictable H-bonding fingerprint for fragment starts and for “pyridine → pyridinone” property benchmarking.
Polyhydroxy pyridinone / highly polar core (multiple H-bond sites)	626-03-9	D110324	2,4-Dihydroxypyridine	≥97%	Polyfunctional H-bond donor/acceptor scaffold (can be viewed as a 4-hydroxy-2-pyridinone tautomeric system): often used to increase polarity and H-bond networking, and can serve as a bioisosteric reference for certain nucleobase-/amide-like interactions.
N-substituted pyridinone / property control (donor shut-off)	694-85-9	M158822	1-Methyl-2-pyridinone	≥99% (GC)	N-alkylation removes the N–H donor, making it an important control for evaluating pyridinone donor/acceptor contributions; also commonly used as a model solvent/fragment for highly polar aprotic environments.
N-substituted + hydroxy pyridinone (polarity/coordination tuning)	40357-87-7	H733848	1-Methyl-4-hydroxy-2-pyridinone	≥98%	A highly polar fragment combining a pyridinone-like carbonyl and a hydroxy group; used to strengthen H-bond networks/coordination and as a “knob” building block for polarity boosting and fine-tuning binding modes.
Representative scaffold / pharmacophore (hydroxypyridinone HPO; metal coordination)	30652-11-0	H122577	1,2-Dimethyl-3-hydroxy-4-pyridinone	Moligand™, ≥98%	Representative 3-hydroxy-4-pyridinone (HPO) motif: a strong coordination/chelating pharmacophore that can markedly increase polarity and provide specific H-bond/coordination patterns; often used as a “property knob” or for probing metal-related targets/mechanisms.
3D-saturated pyridinone fragment (increase Fsp³)	6052-73-9	D194151	5,6-Dihydropyridin-2(1H)-one	≥97%	Saturated (more sp³) pyridinone fragment: used for “Escape from Flatland”-style optimization to increase 3D character and potentially improve selectivity/solubility; also convenient for further functionalization.
Fused / expanded pyridinone-like scaffold (scaffold hopping)	23616-29-7	N698244	1,6-Naphthyridin-2(1H)-one	≥98%	Fused “pyridinone-like” lactam scaffold: commonly used in scaffold hopping and hinge/receptor-binding exploration; tunes HBA/HBD and electronics while keeping size in a comparable range.
Connection-handle block (hydroxynicotinic acid; salt formation & amidation)	609-71-2	H128113	2-Hydroxynicotinic acid	≥99%	Hydroxypyridine carboxylic-acid “handle” block: the carboxylate enables salt formation, amidation, and building analog series; supports parallel SAR expansion and solubility-window optimization.
Connection-handle block (hydroxynicotinic acid; salt formation & amidation)	609-70-1	H128097	4-Hydroxynicotinic acid	≥97%	Hydroxynicotinic acid: carboxylic acid serves as a universal attachment point for amides/esters/salts; suitable for building “pyridinone-like fragment + appended group” series and optimizing solubility and exposure.
Connection-handle block (hydroxypyridinecarboxylic acid)	874-24-8	H137085	3-Hydroxy-2-pyridinecarboxylic acid	≥98%	Hydroxypyridine carboxylic acid: provides a downstream connection point (amidation/salt formation/coupling), facilitating systematic derivatization and property optimization (solubility/distribution).
Polyhydroxy + carboxylic acid block (high polarity/coordination tendency)	99-11-6	C109722	Chelidonic acid	≥97%	Polyhydroxy pyridinecarboxylic acid: highly polar with multiple H-bond sites; often used as an exploration block for “strong polarity/coordination enhancement,” and as a high-polarity control for testing property boundaries.

Table B｜Halogenated, Cross-Coupling-Ready Building Blocks (Entry Points for Expanding 2-Hydroxypyridine / Pyridinone Series)

Category	CAS No.	Aladdin Cat. No.	Name	Spec / Purity	Key properties & uses (pyridinone-related)
Halogenated coupling block (2-hydroxypyridine series)	13472-79-2	W131730	2-Hydroxy-5-iodopyridine	≥97%	High-reactivity C–I coupling block: well-suited for rapid installation of bulky/diverse substituents via Sonogashira/Suzuki and related reactions, accelerating SAR expansion.
Halogenated coupling block (2-hydroxypyridine series)	13466-38-1	B152104	5-Bromo-2-hydroxypyridine	≥98%	A common high-throughput library block (C–Br typically more reactive than C–Cl): suitable for parallel Suzuki/amination workflows to rapidly build 2-pyridinone SAR.
Halogenated coupling block (2-hydroxypyridine series)	27992-32-1	B151966	6-Bromo-2-hydroxypyridine	≥98%	High-reactivity entry block at the 6-position: enables rapid introduction of aryl/heteroaryl/amine substituents for “hinge binding/bioisosteric” derivative exploration.
Halogenated coupling block (2-hydroxypyridine series)	4214-79-3	C136324	5-Chloro-2-hydroxypyridine	≥98% (GC)	Classic entry block (C–Cl): used for Suzuki/Buchwald–Hartwig/certain SNAr and related expansion routes to probe substitution effects and property tuning in 2-pyridinone series.
Halogenated coupling block (2-hydroxypyridine series)	16879-02-0	C153927	6-Chloro-2-hydroxypyridine	≥98%	6-position entry point: supports comparing 5- vs 6-substitution effects on conformation, electronics, and solubility/metabolism—useful for systematic “site scanning.”

Table C｜Representative Drugs / Reference Standards + Supporting Reagents for Metabolic Activation & Safety Assessment

Category	CAS No.	Aladdin Cat. No.	Name	Spec / Purity	Key properties & uses (pyridinone-related)
Metabolic activation / safety assessment reagent (nucleophile trapping)	70-18-8	G105427	Glutathione (reduced) (GSH)	Moligand™, for cell culture, ≥98%	Key endogenous nucleophile; commonly used for in vitro GSH trapping to screen reactive metabolites/covalent-risk pathways—standard reference reagent for evaluating potential “activation liability” in pyridinone series.
Metabolic activation / safety assessment reagent (nucleophile trapping)	616-91-1	A105421	N-Acetyl-L-cysteine (NAC)	PharmPure™, USP, European Pharmacopoeia (Ph.Eur), ≥98.5%	A commonly used nucleophile/antioxidant; used in GSH/NAC trapping or reactive-metabolite risk assessment to help judge whether a pyridinone scaffold may access a “bioactivation → electrophilic intermediate” pathway.
Representative drug / reference standard (pyridinone-containing)	53179-13-8	P129335	Pirfenidone	Moligand™, ≥98% (GC)	Marketed drug containing a pyridone (pyridinone) core; supports clinical feasibility of the motif and can serve as a reference for physicochemical and metabolic behavior.
Representative drug / reference standard (bipyridinone / pyridinone-like lactam)	60719-84-8	A115346	5-Amino-[3,4′-bipyridin]-6(1H)-one (Amrinone)	Moligand™, ≥98%	Classic reference with a bipyridinone (pyridinone-like lactam) core; illustrates that embedding lactam-like H-bond logic into heteroaromatics can help balance activity and properties.
Representative drug / reference standard (pyridinone-containing)	1338225-97-0	D413483	Doravirine (MK-1439)	≥98%	Marketed drug containing a pyridinone motif; often cited as a real-world example of using pyridinone as a bioisostere/physicochemical-tuning module in complex drugs.

Note: The above are representative Aladdin products. For additional specifications, please refer to the full product list at the end of the article or search by product name/CAS on the Aladdin website.

Aladdin: https://www.aladdinsci.com/